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Background/Aims: Antiphospholipid antibodies (aPL) have been detected in various proportions of patients with primary 
immune thrombocytopenia (ITP), but the clinical significance of this is debatable. The present study aimed to determine 
the frequency and clinical implications of elevated aPL in adult patients with ITP.
Methods: We prospectively studied newly diagnosed adult patients with ITP who were enrolled between January 2003 
and December 2008 at Chungnam National University Hospital. They were evaluated for the presence of lupus anticoagu-
lant (LA) and anticardiolipin antibodies (aCL) at diagnosis and were followed for the development of thrombosis.
Results: Seventy consecutive patients with ITP (median age, 48 years; range, 18 to 79) were enrolled. Twenty patients 
(28.5%) were positive for aPL at the time of diagnosis: aCL alone in 15 (75%), aCL and LA in two (10%), and LA alone in 
three (15%). Patients who had platelet counts < 50,000/µL were administered oral prednisolone with or without intravenous 
immune globulin. No difference was found between the aPL-positive and -negative groups regarding gender, initial platelet 
count, and response to the therapy. After a median follow-up of 20 months (range, 2 to 68), two of 20 patients who were 
aPL-positive (10%) developed thrombosis, whereas no thrombotic event was found among those who were aPL-negative.
Conclusions: Our data suggest that aPL levels should be determined at the initial presentation of ITP and that patients 
found to be aPL-positive should receive closer follow-up for thrombotic events.
Keywords: Antibodies, anticardiolipin; Antiphospholipid syndrome; Purpura, thrombocytopenic, idiopathic; Lupus coagula-
tion inhibitor; Thrombosis
INTRODUCTION
Primary immune thrombocytopenia (ITP) is an ac-
quired disorder characterized by isolated thrombocyto-
penia resulting from autoantibody-mediated peripheral 
platelet destruction and the absence of any obvious initiat-
ing and/or underlying cause of the thrombocytopenia [1]. 
Antiphospholipid syndrome (APS) is a thrombotic dis-
order defined by the presence of one or more clinical fea-
tures of arterial or venous thrombosis, recurrent fetal loss, 
and presence of antiphospholipid antibodies (aPL) such as 
anticardiolipin antibody (aCL), lupus anticoagulant (LA), 
and/or anti-b2 glycoprotein-I (anti-b2GPI) [2-4]. Throm-
bocytopenia, as a manifestation of primary APS, has a 
reported prevalence of 20 to 46% [5-7]. Although evidence 
suggests that aPL may bind activated platelet membranes 
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and cause platelet destruction [8,9], the pathogenesis of 
thrombocytopenia related to aPL remains unclear. Con-
versely, elevated levels of aPL have been demonstrated in 
patients with ITP. The reported incidences of aPL in ITP 
vary considerably, ranging from 26 to 75% of cases, which 
can be attributed partly to technical differences [5-8,10-
13]. Furthermore, the clinical significance of aPL in pa-
tients who have ITP is controversial. Recently, an interna-
tional working group reported that measuring aPL is not 
routinely recommended for investigation of ITP [1].
 How-
ever, the prevalence of aPL and its clinical implications in 
ITP have not been studied in Korean populations. Here, 
we performed a prospective study to define the frequency 
and clinical relevance of aPL in a single-center cohort of 
adults with ITP.
METHODS
Patients
We prospectively enrolled patients who were newly di-
agnosed with ITP between January 2003 and December 
2008 at Chungnam National University Hospital. ITP 
was diagnosed based on the guidelines proposed by the 
American Society of Hematology [14]. Only patients aged 
> 18 years who had platelet counts < 100,000/µL and no 
history of other clinical conditions that can cause throm-
bocytopenia were included. All patients underwent a panel 
of laboratory tests, including tests for antinuclear and anti-
virus (cytomegalovirus, Epstein-Barr virus) antibodies, 
and screening for human immunodeficiency virus (HIV), 
and hepatitis B and C virus infection. Peripheral blood 
and bone marrow smears were examined to exclude other 
causes of thrombocytopenia. Patients who had a history of 
arterial or venous thrombosis were excluded. Additional 
exclusion criteria were a history or clinical findings of APS 
fulfilling the international consensus statement criteria 
[3], systemic lupus erythematosus (SLE) satisfying the 
American College of Rheumatology criteria [15,16], other 
autoimmune disorders, malignancies, and concomitant 
viral infections, including HIV or hepatitis C or B virus in-
fection.
Laboratory investigation
Detection of LA
Blood samples were collected in vacuum tubes contain-
ing sodium citrate. Dilute Russell’s viper venom time 
(dRVVT) was used as an initial sensitive screening test 
for LA and as a confirmatory test. Criteria for positive LA 
were based on the guidelines of the Scientific Subcommit-
tee of the International Society on Thrombosis and Hae-
mostasis [17]. Patients in whom a ratio > 1.2 (test dRVVT/
control dRVVT) was obtained were considered to be posi-
tive.
Detection of aCL
Blood samples were collected in serum tubes. IgM-
aCL and IgG-aCL tests were performed using an enzyme-
linked immunosorbent assay (ELISA) for semiquantitative 
detection in human sera. The values of aCL are expressed 
in MPL and GPL (units of IgM-aCL and IgG-aCL, respec-
tively). Twenty GPL units/mL for IgG and 20 MPL units/
mL for IgM were considered to be positive results.
Treatment of ITP
Patients with platelet counts < 50,000/mL were placed 
on prednisolone (PD) therapy. PD was administered at a 
dose of 1 mg/kg/day for 4-6 weeks, and then was tapered. 
In patients with initial platelet counts < 20,000/mL, in-
travenous immune globulin (IVIg) was administered at a 
dose of 400 mg/kg/day for 5 days in combination with PD. 
Splenectomy was performed in patients who were refrac-
tory to PD. Response was defined as 1) a platelet count ≥ 
100,000/µL at the last clinic visit, when the initial platelet 
count was > 50,000/µL; or 2) a platelet count increase of 
≥ 20,000/µL from baseline to a final value > 50,000/µL. 
Responses lasting < 3 and ≥ 3 months after the initiation 
of treatment were defined as transient and sustained re-
sponses, respectively. 
Follow-up
Eligible patients were monitored every 1-2 weeks for the 
first 3 months and then every 1-3 months for the remain-
ing period, to conduct laboratory investigations and check 
for the development of arterial or venous thrombotic 
events. A complete blood count was determined at every 
visit. Routine chemistry, urine analysis, studies to exclude 
SLE, and aPL tests were performed 12 months apart. yang yJ, et al. Antiphospholipid antibodies in ITP     451
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Statistical analysis
Characteristics, response to treatment, and frequency 
of thrombosis were compared between aPL-positive and 
-negative patients using the chi-square test as appropriate 
for categorical variables and Student’s t test for continuous 
variables. A p value < 0.05 was considered to indicate sig-
nificance. All analyses were performed using SPSS version 
17.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
Patient characteristics and frequency of aPL at the 
time of ITP diagnosis
Seventy patients were enrolled. The median age was 
48 years (range, 18 to 79), and 45 patients (64.3%) were 
female. Most of the patients (91.4%) had platelet counts < 
50,000/mL (Table 1). Of these, aPL (aCL and LA) were de-
tected in 20 patients (28.5%): aCL alone in 15 (75%), aCL 
and LA in two (10%), and LA alone in three (15%). Of the 
15 patients who were positive for aCL only, eight had IgG-
aCL only, four had IgM-aCL only, and three had both IgM- 
and IgG-aCL. LA was detected in a total of five patients 
and was associated with aCL in two (Table 2). Age, gender, 
and platelet count did not differ between the aPL-positive 
and -negative groups (Table 1). 
Response to treatment
Sixty-four of the 70 patients (17 aPL-positive; 47 aPL-
negative) received PD therapy with or without IVIg. Six of 
the 70 (those with initial platelet counts > 50,000/µL) did 
not receive any therapy. All patients who received therapy 
exhibited a transient or sustained response. Both tran-
sient and sustained response rates were similar between 
the aPL-positive and -negative groups (Table 3). The time 
to response did not differ between the aPL-positive and 
Table 1. Patient characteristics at the time of ITP diagnosis
Characteristics All aPL-positive aPL-negative p value
a
No. of patients 70 20 50
Age, median (range), yr   48 (16-79)      45 (20-76)      49 (16-79) 0.432
Gender
Male 25  9 16
0.305
Female 45 11 34
Platelet count, /mL
Mean ± SD 14,360 ± 17,000 16,250 ± 16,800 13,600 ± 18,000 0.573
< 50,000, n (%) 64 (91.4) 18 (90) 46 (92)
0.830
≥ 50,000, n (%) 6 (8.6)   2 (10) 4 (8)
ITP, immune thrombocytopenia; aPL, antiphospholipid antibody.
ap value between the aPL-positive and -negative groups.
Table 2. Distribution of elevated aPL at ITP diagnosis
aPL status
All patients
(n = 70)
Platelet count, /μL
< 50,000 (n = 64) ≥ 50,000 (n = 6)
IgG-aCL  8 (11.4) 7 (10.9) 1 (16.7)
IgM-aCL 4 (5.7) 3 (4.7) 1 (16.7)
IgG-aCL + IgM-aCL 3 (4.3) 3 (4.7) 0 (0)
LA + IgG-aCL 1 (1.4) 1 (1.6) 0 (0)
LA + IgM-aCL 1 (1.4) 1 (1.6) 0 (0)
LA + IgG-aCL + IgM-aCL 0 (0) 0 (0) 0 (0)
LA 3 (4.3) 3 (4.7) 0 (0)
Total 20 (28.5) 18 (28.1) 2 (33.3)
Values are presented as number (%).
aPL, antiphospholipid antibody; ITP, immune thrombocytopenia; aCL, anticardiolipin antibody; LA, lupus anticoagulant.452    The Korean Journal of Internal Medicine Vol. 26, No. 4, december 2011
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-negative groups, regardless of treatment modality (Table 
3).
Status of aPL during follow-up
Most patients (88.5%; 62 of 70) were followed with aPL 
tests 12 months apart, 85.0% (17 of 20) in the aPL-positive 
group and 90.0% (45 of 50) in the aPL-negative group. No 
patient who was aPL-positive at the time of ITP diagno-
sis lost aPL positivity, and none of those who were aPL-
negative at the time of ITP diagnosis displayed aPL during 
follow-up (data not shown). 
Thrombotic events during follow-up
The median follow-up periods in the aPL-positive and 
-negative groups were 19.6 (interquartile range, 15.5 to 
27.5) and 20.7 (18.7 to 28.1) months, respectively. The 50 
patients who did not have aPL at diagnosis did not dis-
play thrombotic events during a median follow-up of 20 
months (range, 2 to 68). In contrast, two of the 20 aPL-
positive patients (11%) experienced thrombotic events 
(Table 3).
A 54-year-old man who had atrial fibrillation developed 
acute myocardial infarction 2 months after diagnosis of 
ITP. Platelet counts at diagnosis and the thrombotic event 
were 39,000/mL and 61,000/mL, respectively. He had IgM-
aCL, but not LA or IgG-aCL, at diagnosis of ITP. He had 
discontinued PD 2 weeks before the thrombotic episode. 
He underwent successful intracoronary stenting and re-
ceived aspirin as prophylaxis. Another patient, a 56-year-
old woman, had LA, a high level of IgM-aCL (29.7 MPL 
Table 4. Characteristics of the two patients who developed thrombosis
No. Age Gender
At diagnosis follow-up (12 mon apart) At development of thrombosis
Cardiovascular risk 
factors PLT, /mL LA IgG-aCL IgM-aCL Type
Months after 
diagnosis
PLT, /mL
1 54 Male   39,000 - - + AMI 2 61,000 Atrial fibrillation
  78,000 - - +
2 56 Female   31,000 + - + DVT 5 12,000 Obesity
105,000 + - +
PLT, platelet count; LA, lupus anticoagulant; aCL, anticardiolipin antibody; AMI, acute myocardial infarction; DVT, deep vein thrombosis.
Table 3. Response to treatment and clinical course according to aPL status
Outcomes
Total
(n = 70)
aPL-positive
(n = 20)
aPL-negative
(n = 50)
p value
a
Treatment No 6 (8.6)   3 (15.0)      3 (6.0)
0.188
yes 64 (91.4)  17 (85.0)        47 (94.0)
Response
IVIg + PD Transient response 26/55 (47.3) 8/15 (53.3) 18/40 (45.0)
0.581
Sustained response 29/55 (52.7) 7/15 (46.7) 22/40 (55.0)
Pd Transient response 4/9 (44.4) 1/2 (50.0)     3/7 (42.9)
0.236
Sustained response 5/9 (55.6) 1/2 (50.0)    4/7 (57.1)
Overall Transient response 30/64 (46.9) 9/17 (52.9)  21/47 (44.7)
0.409
Sustained response 34/64 (53.1) 8/17 (47.1) 26/47 (55.3)
Time to response, day
IVIg + PD - 2.3 (1-12)     2.9 (1-15) 0.716
Pd - 7.3 (2-26)     5.9 (1-34) 0.496
Splenectomy 4 (5.4)  1 (5.0)      3 (6.0) 0.871
Thrombotic event 2 (2.9)   2 (10.0)   0 (0) 0.023
Values are presented as number (%) or median (range).
aPL, antiphospholipid antibodies; IVIg, intravenous immune globulin; PD, prednisolone.
ap value between the aPL-positive and -negative groups. yang yJ, et al. Antiphospholipid antibodies in ITP     453
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units/mL), and obesity. She developed deep vein thrombo-
sis (DVT) 5 months after the diagnosis of ITP. Her platelet 
counts at diagnosis and the thrombotic event were 31,000/
mL and 12,000/mL, respectively. She was taking PD at the 
time of development of DVT. No patient received IVIg, da-
nazol, or underwent splenectomy during the 2 weeks pre-
ceding the thrombotic events (Table 4). Although the two 
patients had risk factors other than aPL for thrombosis, 
thrombotic risk factors did not differ as a function of aPL 
status (Table 5). 
Pregnancy during follow-up
Among the 27 women of child-bearing age, seven (25%) 
were aPL-positive, and three had become pregnant after a 
median follow-up of 37 months (range, 10 to 86). No mis-
carriage occurred in either the aPL-negative or -positive 
groups (data not shown).
DISCUSSION
A variable number of patients with ITP have aPL at the 
time of diagnosis and during follow-up after treatment. In 
the present study, more than one-fourth of patients with 
ITP (28.5%) had aPL at the time of diagnosis. This was 
similar to or lower than previously reported rates [5-8,10-
13]. The reason underlying this discrepancy is not clear. 
Additionally, controversy still exists regarding the clinical 
significance of aPL in these patients. Nevertheless, bleed-
ing manifestations, platelet counts, and response to cor-
ticosteroid treatment have been repeatedly demonstrated 
to not differ as a function of aPL status at the time of di-
agnosis. The present study confirmed that the presence or 
absence of aPL was not associated with a specific clinical 
presentation and did not affect treatment responses in pa-
tients with ITP.
Thrombocytopenia has been reported to have a preva-
lence of 20 to 46% in patients with primary APS [5-7]. 
Since the first definitive clinical and pathological descrip-
tion of APS [18], the association between aPL and the de-
velopment of thrombosis has been extensively investigated 
over decades in patients with APS. However, previous 
studies of aPL in ITP have been limited, compared with 
those in APS, and only a few clinical studies have exam-
ined the relationship between aPL positivity and risk for 
thrombosis. A prospective study on 149 patients with ITP 
could identify no relationship between thrombosis and 
aPL positivity [8]. In contrast, a similarly designed study 
involving 82 consecutive patients with ITP reported that 
aPL-positive patients had a greater incidence of thrombo-
sis over a 5-year period (61 vs. 2.3%) [6]. In another study 
on 216 patients with ITP, 14 of 55 (25%) aPL-positive pa-
tients developed thrombosis over a 2.5-year period [13]. In 
that study, investigators emphasized that thrombosis was 
associated with LA, a high IgG-aCL level, and younger age 
(i.e., < 45 years) at the time of thrombosis. We found that 
two of 20 patients (10%) who were initially positive for aPL 
experienced thrombosis during follow-up. One patient 
had venous thromboembolism, and the other had arterial 
thrombosis. No correlation was found between thrombotic 
events and types of aPL, platelet count, steroid therapy, 
or age. Patients who were initially negative for aPL never 
Table 5. Risk factors for thrombosis according to aPL status
Risk factors
aPL-positive
(n = 20)
aPL-negative
(n = 50)
p value
a
Hypertension   3 (15)   5 (10) 0.553
diabetes mellitus 1 (6) 3 (6) 0.871
Hypercholesterolemia 1 (6) 4 (8) 0.660
Smoking   2 (10)   7 (14) 0.652
Infection 1 (6) 3 (6) 0.871
Surgery 0 (0) 2 (4) 0.364
Malignancy 0 (0) 1 (2) 0.524
Obesity   3 (15) 4 (8) 0.378
Values are presented as number (%).
aPL, antiphospholipid antibodies.
ap value between the aPL-positive and -negative groups.454    The Korean Journal of Internal Medicine Vol. 26, No. 4, december 2011
http://dx.doi.org/10.3904/kjim.2011.26.4.449 http://www.kjim.or.kr
experienced thrombosis. These results provide evidence of 
an increased risk for thromboembolic events in adult aPL-
positive ITP patients compared with aPL-negative ITP 
patients. Contrary to some early reports, individuals with 
elevated aPL showed a much lower rate of thrombosis in 
the present study. This may be attributable to the relatively 
short follow-up duration and comparatively small size of 
the patient population. It is difficult to discuss the relation-
ship between steroid use and thrombotic events for the 
same reasons. Whether prophylactic antithrombotic treat-
ment is beneficial in aPL-positive ITP patients remains 
uncertain, and prospective studies are required. 
In summary, the presence of aPL is a common finding 
in Korean populations with ITP who share similar clini-
cal profiles regardless of aPL status. Although the risk for 
thrombosis was not high, the development of thrombosis 
in aPL-positive, but not aPL-negative, patients suggests 
that measurement of aPL should be considered in ev-
ery newly diagnosed ITP patient. Additional studies are 
needed to determine whether prophylactic anticoagulation 
treatment is beneficial for aPL-positive patients.
Conflict of interest
No potential conflict of interest relevant to this article 
was reported.
Acknowledgments
This study was financially supported in 2006 by the re-
search fund of Chungnam  National University.
REFERENCES
1.  Provan D, Stasi R, Newland AC, et al. International consensus 
report on the investigation and management of primary im-
mune thrombocytopenia. Blood 2010;115:168-186.
2.  Font J, Lopez-Soto A, Cervera R, et al. The ‘primary’ antiphos-
pholipid syndrome: antiphospholipid antibody pattern and clin-
ical features of a series of 23 patients. Autoimmunity 1991;9:69-
75.
3.  Miyakis S, Lockshin MD, Atsumi T, et al. International con-
sensus statement on an update of the classification criteria for 
definite antiphospholipid syndrome (APS). J Thromb Haemost 
2006;4:295-306.
4.  Udayakumar N, Ezhilan N, Rajendiran C. Primary antiphos-
pholipid antibody syndrome: how certain can you be of the 
diagnosis? J Clin Rheumatol 2007;13:53.
5.  Ballerini G, Gemmati D, Moratelli S, Morelli P, Serino ML. 
Anticardiolipin antibody-related thrombocytopenia: persistent 
remission after splenectomy. Haematologica 1995;80:248-251.
6.  Diz-Kucukkaya R, Hacihanefioglu A, Yenerel M, et al. Antiphos-
pholipid antibodies and antiphospholipid syndrome in patients 
presenting with immune thrombocytopenic purpura: a pro-
spective cohort study. Blood 2001;98:1760-1764.
7.  Bidot CJ, Jy W, Horstman LL, Ahn ER, Yaniz M, Ahn YS. An-
tiphospholipid antibodies (APLA) in immune thrombocytope-
nic purpura (ITP) and antiphospholipid syndrome (APS). Am J 
Hematol 2006;81:391-396.
8.  Arfors L, Winiarski J, Lefvert AK. Prevalence of antibodies to 
cardiolipin in chronic ITP and reactivity with platelet mem-
branes. Eur J Haematol 1996;56:230-234.
9.  Font J, Cervera R, Lopez-Soto A, et al. Anticardiolipin antibod-
ies in patients with autoimmune diseases: isotype distribution 
and clinical associations. Clin Rheumatol 1989;8:475-483.
10.  Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of 
the World Health Organization (WHO) classification of myeloid 
neoplasms and acute leukemia: rationale and important chang-
es. Blood 2009;114:937-951.
11.  Stasi R, Stipa E, Masi M, et al. Prevalence and clinical signifi-
cance of elevated antiphospholipid antibodies in patients with 
idiopathic thrombocytopenic purpura. Blood 1994;84:4203-
4208.
12.  Kaburaki J, Kuwana M, Ikeda Y. Anti-cardiolipin-beta2-GPI 
complex antibodies in idiopathic thrombocytopenic purpura. 
Intern Med 1998;37:796.
13.  Pierrot-Deseilligny Despujol C, Michel M, Khellaf M, et al. An-
tiphospholipid antibodies in adults with immune thrombocyto-
penic purpura. Br J Haematol 2008;142:638-643.
14.  George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombo-
cytopenic purpura: a practice guideline developed by explicit 
methods for the American Society of Hematology. Blood 
1996;88:3-40.
15.  Page H. New criteria for diagnosing SLE. JAMA 1982;248:622.
16.  Hochberg MC. Updating the American College of Rheumatol-
ogy revised criteria for the classification of systemic lupus ery-
thematosus. Arthritis Rheum 1997;40:1725.
17.  Pengo V, Tripodi A, Reber G, et al. Update of the guidelines for 
lupus anticoagulant detection. Subcommittee on Lupus Antico-
agulant/Antiphospholipid Antibody of the Scientific and Stan-
dardisation Committee of the International Society on Throm-
bosis and Haemostasis. J Thromb Haemost 2009;7:1737-1740.
18.  Hughes GR. The anticardiolipin syndrome. Clin Exp Rheuma-
tol 1985;3:285-286.